NKTR - Nektar Therapeutics
IEX Last Trade
1.27
0 0%
Share volume: 560,725
Last Updated: Fri 30 Aug 2024 09:59:49 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.27
0.00
0.00%
Fundamental analysis
21%
Profitability
0%
Dept financing
17%
Liquidity
75%
Performance
30%
Performance
5 Days
-5.19%
1 Month
-7.91%
3 Months
1.59%
6 Months
77.78%
1 Year
113.33%
2 Year
-68.24%
Key data
Stock price
$1.27
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.41 - $1.93
52 WEEK CHANGE
$1.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Howard Robin
Region: US
Website: http://www.nektar.com/
Employees: 820
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.nektar.com/
Employees: 820
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Recent news